pharma · ALKEM

Alkem Laboratories

Alkem Laboratories: PE above historical average. NARROW LEADERSHIP regime. sector leading.

Price

₹5,816.5

Price 2026-07-30

5 day

+3.25%

Short-term move

1 month

+4.43%

Medium-term

Regime

NARROW LEADERSHIP

62% confidence

Market cap

₹67.8k Cr

inflow sector flow

Market Intelligence Analyst

Understand today's market in about 2 minutes.

How does today's NARROW LEADERSHIP regime affect Alkem Laboratories (ALKEM) in the pharma sector?

Ask about this stock

Price chart

5,652

+15.54% over period

2025-06-304,595 – ₹5,9352026-07-28

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.

Drug Manufacturers - Specialty & GenericMumbai, India19,346 employeesWebsite →

At a Glance

ValuationPE 29.4 (57%ile of 7 quarterly points (limited history), range 21-67). Trading near median.
Sector Positionpharma sector. Flow: inflow. is in the leaders group. Regime: NARROW LEADERSHIP (62%).
Historical ContextRSI oversold bounces for this stock succeeded only 0% of the time (avg -6.7% over 14 days) — not a reliable pattern.
Revenue TrendRevenue growing at 1460.0% YoY. Strong revenue growth — 1460.0% YoY

RSI pattern warning

RSI oversold bounces for this stock succeeded only 0% of the time (avg -6.7% over 14 days) — not a reliable pattern.

52-week position

Trading at 98% of 52-week high

52W low ₹4,716.252W high ₹5,933.5

Technicals

RSI 14

58.4

Trend

uptrend

50 DMA

Above

200 DMA

Above

Key metrics

P/E ratio

29.4

57th pct · 7 quarterly points (limited history)

P/B

4.9

ROE

17.6%

Moderate profitability — 17.6% ROE

Market cap

₹67.8k Cr

Revenue growth

1460.0% YoY

Promoter

62.9%

52-week range

₹4,716.2 – ₹5,933.5

98% of high

RSI (14)

58.4

uptrend

vs 50 DMA

Above

DMA ₹5,486.58

Coverage

100/100

HIGH

Quick Take

Alkem Laboratories: PE above historical average. NARROW LEADERSHIP regime. sector leading.

Peer comparison

StockPrice5DP/EROERev growthMcap
DIVISLAB

Divi's Laboratories

₹7,835+7.7%7016.2%950%₹1.8L Cr
CIPLA

Cipla

₹1,466.4+5.3%30.211.7%-210%₹1.2L Cr
DRREDDY

Dr. Reddy's Laboratories

₹1,144.8-1.8%26.511.8%-1160%₹1.1L Cr
AUROPHARMA

Aurobindo Pharma

₹1,576.3+3.5%26.39.9%560%₹91.1k Cr
BIOCON

Biocon

₹425.35-2.3%145.31.1%230%₹66.3k Cr
GLENMARK

Glenmark Pharmaceuticals

₹2,190.3-0.7%4714.1%1430%₹63.9k Cr
GLAND

Gland Pharma

₹2,517+5.9%40.910.5%2230%₹42.1k Cr
JBCHEPHARM

J B Chemicals

₹2,408.9+0.0%54.518.7%-480%₹38.9k Cr
ALKEM

Alkem Laboratories

₹5,816.5+3.8%29.417.6%1460%₹67.8k Cr

Key Watchpoints

🟢

Breaks above ₹6107 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹5526 (-5%)

Further downside risk

🟡

PE reverts to median of 28.1 (7 quarterly points (limited history))

Valuation normalization

🟢

Pharma sector holding leadership position

Sector momentum continuing

Facts

P/E Ratio
29.4MODERATE
P/B Ratio
4.9HIGH
ROE
1756.0%HIGH
Market Cap
₹6776346.4L CrHIGH
From 52W High
98% of high
Promoter Holding
62.9%MODERATE
Institutional
25.1%
Sector Peers
10
FinGenieFinGenie

Understand today's market in about 2 minutes. Ask your analyst